Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$126.27 USD

126.27
146,545

+1.85 (1.49%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

BDX Stock Declines Despite Launching BD IO Vascular Access System

BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.

Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance

SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.

ECL Q3 Earnings Surpass Estimates, Revenues Miss, Margins Rise

Ecolab's robust performance across the majority of its segments drives its third-quarter sales.

AMIS Stock Surges After RF Ablation Trial Unveils Positive Results

Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.

Here's Why You Should Add Veeva Stock in Your Portfolio Now

VEEV's robust product portfolio raises optimism about the stock. However, escalating costs are concerning.

U.S. Physical Therapy (USPH) Reports Next Week: Wall Street Expects Earnings Growth

U.S. Physical Therapy (USPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALGN Stock Rise on the Release of Invisalign Smile Architect Software

Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.

Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products

XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.

Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integer Holdings Q3 Earnings Surpass Estimates, Revenues Up Y/Y

ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.

ALUR Stock Declines Despite Submitting PMA for Allurion Balloon

Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.

Talkspace Shares Decline Despite Partnership With Wisdo Health

TALK collaborates with Wisdo Health to enhance mental health support for seniors, addressing loneliness and improving access to care for the 65+ community.

LifeMD Shares Decline Even After the Launch of Testosterone Therapy

LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.

ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls

Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.

Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare

Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare have been highlighted in this Industry Outlook article.

ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

AngioDynamics announces the receipt of CPT Category I code for IRE technology.

Reasons to Retain Ecolab Stock in Your Portfolio for Now

ECL's focus on cost-efficiency programs raises optimism about the stock.

Debanjana Dey headshot

4 Stocks to Buy in an Evolving Outpatient Home Health Industry

Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.

Revvity Shares Decline Despite Launch of Transcribe AI Solution

RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

GEHC Stock Declines Despite the Unveiling of CareIntellect Application

GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.

iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT

IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.

Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval

BSX receives FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing cardiac mapping and ablation workflows for AF treatment.

Myriad Genetics Shares Fall Despite Partnership With jscreen

MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.

Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch

ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.